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Introduction
TRAPS is a genetic disorder characterised by recurrent
attacks of fever, abdominal and muscle pain and rash,
most common in patients of northern European origin.1
Very little is known about the patient experience with
TRAPS.
Objectives
To qualitatively assess the burden of disease on patients
and caregivers and describe patient’s journey.
Patients and methods
TRAPS patients or caregivers (paediatric patients) (N=16)
were recruited via rare disease experts and patient groups.
A 20 page pre-interview questionnaire and in-depth
90 minute interview were completed. Complete data
(n=15) were quantified with topics focused on symptoms,
diagnosis, burden, treatment experience and unmet needs.
Results
Most patients were female (n=13) and had a family history
of TRAPS (n=9). Physical functioning was greatly impaired
during an attack with most common symptoms including
fever, abdominal pain, joint pain, rash, vomiting and diar-
rhoea. Fever was the most prominent symptom in children
and muscle and joint pain in adults. Paediatric patients
reported missing school due to attacks or attending medi-
cal appointments were common. Adults frequently missed
work for similar reasons, resulting in anxiety over work
due to frequent absences. Damage to education or career
had a negative financial impact as did travelling long dis-
tances to medical appointments. Social activities were also
restricted, creating a sense of isolation, embarrassment
and uncertainty. Delay in diagnosis was frequently
reported with time to diagnosis greater than five years in
more than 50% of patients. Steroids are typically the first
treatment, while providing temporary relief may lead to
uncertainly of long-term side effects, Biologics, typically
IL-1 or TNF-alphas, are initiated subsequently and major-
ity of patients reported a decrease in severity and fre-
quency of attacks. Common concerns include, injection
site reactions, increased susceptibility to infection, and
maintenance of efficacy. Patients expressed interest in
alternative administration and storage conditions as poten-
tial ways to ease the burden of management. Finally, an
increase in disease awareness was important, as many
patients receive little information about their condition
and are often required to do their own research, perhaps
due to lack of physician awareness.
Conclusions
The study demonstrated that the burden of TRAPS is
considerable, impacting physical, social, emotional and
practical/financial aspects of patients’ and caregivers
lives. Greater physician disease awareness may lead to
improvements in diagnosis. Finally, improved therapeutic
options with alternative modes of administration are
needed for the treatment of TRAPS.
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